Rituximab and ocrelizumab go head to head in randomized trial ...

A Norwegian-Swedish clinical trial published in the New England Journal of Medicine demonstrates that rituximab, a low-cost B ...

Increasing the Ocrevus dose used in treating MS provided no additional benefit versus the approved regimen in trials with over 1,500 patients.

- MUSETTE trial was designed to determine whether a higher dose of the currently approved Ocrevus IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosis - - The ...

Following treatment with TG Therapeutics’ Briumvi, patients reported improvements in satisfaction and quality of life.

Frexalimab (Sanofi), a novel, investigational second-generation inhibitor of the CD40 ligand, significantly reduced disease activity in relapsing multiple sclerosis (MS) and was well tolerated in a ...

The National Institute for Health and Care Excellence (NICE) has updated its guidance on the use of cladribine (Mavenclad, Merck) for patients with rapidly evolving severe relapsing-remitting multiple ...

New research led by a St. Michael's Hospital clinician-scientist and published in the New England Journal of Medicine suggests that a therapy called Tolebrutinib could reduce disability progression in ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...

Sponsored by Novartis Jamie Lynn Sigler opens up about self-advocacy, finding her treatment plan and why your voice should be ...

A Norwegian Swedish clinical trial published in the New England Journal of Medicine (NEJM) demonstrates that rituximab, a low ...